IAP7 Rec'd PCT/PTO 28 AUG 2006

| | AP | | HeC | ar | | 114 | 10 | 20 | AUG | |
|--------------------|-------|---|--------|-------|------|-----|----|----|-----|--|
| LING BY "EXPRESS N | MAIL" | U | VDER 3 | 7 CFR | 1.10 | 0 | | | | |

| \$.0 | TION (O D) | | | | | | |
|--------------|--------------|-----------------|--|--|--|--|--|
| EV67811 | 2757US | 28 August 2006 | | | | | |
| Express Mail | Label Number | Date of Deposit | | | | | |
| | | | | | | | |

| Form PTO-1390-MOD U. S (REV 10-96) | . Department of Commerce Patent and Trademark Office | ATTORNEY'S DOCKET NUMBER 33668US-PCT | | | | | | | |
|--|---|--------------------------------------|--|--|--|--|--|--|--|
| TRANSMITTAL LETTER TO | U.S. APPLICATION NO. (If known, see 37 CFR 1.5 | | | | | | | | |
| DESIGNATED/ELECTED C | FFICE (DO/EO/US) | 40/50000 | | | | | | | |
| CONCERNING A FILING UI | NDER 35 U.S.C. 371 INTERNATIONAL FILING DATE | 10/590889 | | | | | | | |
| INTERNATIONAL APPLICATION NO. PCT/EP2005/002108 | PRIORITY DATE CLAIMED 1 March 2004 (01.03.04) | | | | | | | | |
| TITLE OF INVENTION | | | | | | | | | |
| PHARMACEUTICAL FORMULATION | | | | | | | | | |
| APPLICANT(S) FOR DO/EO/US SVETE ET AL. | | | | | | | | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | | | | | | | | |
| This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)): are transmitted herewith (required only if not transmitted by the International Bureau). | | | | | | | | | |
| c. have not been made; however, to have not been made and will not a have not been made; however, to have not been made and will not a have not been made and will not be not be not been made and will not be not be not been made and will not be not been made and will not be not be not been made and will not be not be not been made and will not be not be not been made and will not be not be not been made and will not be not be not been made and will not be not been made and will not be not be not been made and will not be not be not be not been made and will not be not be not been made and wil | ☐ An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. | | | | | | | | |
| Items 11. to 16. below concern document(s) of | | | | | | | | | |
| _ | . An Information Disclosure Statement under 37 CFR 1.97 and 1.98. | | | | | | | | |
| 12. An assignment document for recording. | An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. | | | | | | | | |
| 13. ☐ A FIRST preliminary amendment.☐ A SECOND or SUBSEQUENT prelimina | ⚠ A FIRST preliminary amendment. ☐ A SECOND or SUBSEQUENT preliminary amendment. | | | | | | | | |
| 14. 🛛 An Application Data Sheet under 37 CFI | An Application Data Sheet under 37 CFR 1.76. | | | | | | | | |
| 15. A substitute specification. | A substitute specification. | | | | | | | | |
| 16. A change of power of attorney and/or ad | ☐ A change of power of attorney and/or address letter. | | | | | | | | |
| 17. A computer-readable form of the sequer | A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. | | | | | | | | |
| 18. A second copy of the published Internati | ☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4). | | | | | | | | |
| 19. A second copy of the English language | A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4). | | | | | | | | |
| 20. Other items or information: Unexecuted | 9 " | | | | | | | | |
| | | | | | | | | | |

4° - 3

IAP9 Rec'd PCT/PTO 28 AUG 2006

| U.S. APPLICATION NO | 175 | उ न्हें है | | INTERNATIONAL APPLICATION NO. ATTORNEY'S D PCT/EP2005/002108 33668US-I | | | | OCKET NUMBER PCT | | | |
|---|-------------------------|----------------------------------|---------------|--|-------------|-----------------|----------------|------------------|------------------|-------------|--|
| The following fe | es are su | ubmitted: | | | | | | | ULATIO | NS PTO USE | |
| ď | | | | | | | | ONLY | | | |
| 21. 🛛 Basic national fee | | | | | | | | | | | |
| 22. Examination Fee If International preliminary examination report was prepared by USPTO | | | | | | | | | | | |
| ∐ If Interest in the Land | ernationa all claims | al preliminary s satisfy prov | examination | report was prepared by U Article 33(1)-(4) | | , | \$ | | | | |
| | | | | | | | \$200 | | | | |
| ⊠ All'oʻ | tner situa | itions | | | | •• | Ψ200 | | | | |
| 23. Search fee | | | 3. | | | | | | | | |
| ☐ If Se | arch fee | (37 CFR 1.4 | 45(a)(2)) has | been paid on the internat | ional | | • | | | | |
| appli ⊠ If Int | cation to | the USPTO | as an Interna | ational Searching Authority pared and provided to the | / Office | | \$ \$400 | | | | |
| | | | | | | | \$ | | | | |
| TOTAL OF 21, 22 AND 23 = | | | | | | | | \$ | 900 | | |
| Additional fee fo | r specifi | cation and dr | | n paper over 100 sheets (| exclud | lina sea | uence listing | or comp | uter | | |
| program listing to | filed in a | n electronic r | nedium). The | e fee is \$250 for each add | itional | 50 shee | ets of paper o | fraction | 1 | | |
| Total Sheets | Extra | | | ach additional 50 or fractio | n | F | RATE | | | | |
| - 100 = | | /50 = | tnereor (roun | d up to a whole number) | | X \$ | 250 | \$ | | | |
| | | | | | | | | | | | |
| Surcharge of \$1 months from the | | | | | | | | \$ | | | |
| CLAIMS | | NUMBE | R FILED | NUMBER EXTRA | | RA | | | | | |
| Total claims | | 12 | - 20 = | 0 | X | - \$ | 50 | \$ | | | |
| Independent cla MULTIPLE DEF | | T CLAIM(S) | | | + | \$ | 360 | \$ | | | |
| | | | | TOTAL OF ABOVE | CAL | CULA | TIONS = | \$ | 900 | | |
| Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be | | | | | | | ıst also be | \$ | | | |
| filed (Note 37 CFR 1.9, 1.27, 1.28). | | | | | | | \$ | 900 | | | |
| Processing fee | of \$130 f | or furnishing | the English t | ranslation later than | 30 mo | nths from | | | | | |
| earliest claimed priority date (37 CFR 1.492(f)). + TOTAL NATIONAL FEE = | | | | | | | \$ | 900 | | | |
| T. f din | - 45 | alanad annia | nmont (37 CE | FR 1.21(h)). The assignment | | | | 4 | 900 | | |
| by an appropria | ig the en te cover | sheet (37 CF | FR 3.28, 3.31 |). \$40 per property | | ast De at | + | \$ | | | |
| by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property + TOTAL FEES ENCLOSED = | | | | | | | \$ | 900 | | | |
| | | | | | | | | | nount to | \$ | |
| | | | | | | | | | funded harged | \$ | |
| a. | k in the | amount of \$ | · | to cover the above fee | es is e | nclosed | | | V : | | |
| | | | | | | | | cover th | ne above | fees. A | |
| b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$900 to cover the above fees. A duplicate copy of this form is enclosed. | | | | | | | | | | | |
| c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis. | | | | | | | | | | | |
| NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. | | | | | | | | | | | |
| Send all correspondence to the address associated with | | | | | | | | | | | |
| Customer No. 001095, which is currently: | | | | | | | | | | | |
| | | | | | | hallemei | • | | <u> '</u> | | |
| Novartis Attorney for Applicants | | | | | | • | | | | | |
| Corporate Intellectual Property Reg. No. 34,940 One Health Plaza, Building 104 (609) 627-8507 | | | | | | | | | | | |
| East Hanover, NJ 07936-1080 | | | | | | | | | | | |
| | | | | | | | | | | | |